Overview

Second-Line Treatment Choice for Epilepsy

Status:
Unknown status
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
Most patients are prescribed valproate as their first antiepileptic drug. It is unknown which is the best second-line drug when patients do not become seizure free on valproate. This has led the Dutch Epilepsy Clinics Foundation (SEIN) to start the SLICE study. Adult patients with partial and/or tonic-clonic seizures, insufficiently responding to valproate, are recruited for this study. These patients are randomized to receive one of three other drugs. Patients wil initially use this drug next to valproate. Neurologists of more than 20 general hospitals en neurologists of SEIN are participating in this study.
Phase:
N/A
Details
Lead Sponsor:
Dutch Epilepsy Clinics Foundation
Treatments:
Carbamazepine
Etiracetam
Lamotrigine
Levetiracetam